

MERUS LABS INTERNATIONAL INC. OBTAINS APPROVAL FOR COLLEXA®

(CNSX: MR)

VANCOUVER, September 12, 2011 /CNW/ - **Merus Labs International Inc.** ("Merus" or the "Company") is pleased to announce that Health Canada has approved its advanced wound care product Collexa®. Collexa® is exclusively licensed to Merus Labs by Innocoll for sales and distribution in Canada.

Collexa is an advanced bilayer wound care device comprising a layer of white collagen matrix with a backing layer of absorbent polyurethane foam. The collagen matrix layer aids in the wound management while the polyurethane foam layer acts as a reservoir absorbing wound fluids. Collexa can absorb greater than ten times its own weight in wound fluids.

Collexa may be used for the management of wounds including: Diabetic ulcers, venous ulcers, pressure ulcers, ulcers caused by mixed vascular etiologies, full thickness & partial thickness wounds, abrasions, traumatic wounds, 1st and 2nd degree burns and surgical wounds. Including Collexa®, Merus currently has 8 wound care products that will be launched in the current quarter. "With the approval of Collexa®, Merus will provide Canadian patients with a stronger pipeline of products designed to greatly advance wound care treatment. We greatly appreciate the diligent work of our partners Innocoll and Methapharm in advancing the approval of Collexa® and launch of our line of wound care products in this quarter." said Ahmad Doroudian, President and CEO.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

About Innocoll Inc: Innocoll is an international biopharmaceutical company focused on targeted delivery products primarily in the areas of biodegradable surgical implants and topically applied healthcare products. The company has developed and manufactures a range of pharmaceutical products and medical devices using their proprietary collagen-based technologies.

Forward-looking Statements:

This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with securities regulatory authorities.

For further information:

Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.

Tel: (604) 805-7783

adoroudian@meruslabs.com